UK – NICE issues two recommendations for UCB’s inflammatory disease drug

Bimzelx, which is already authorised in the UK to treat certain patients with plaque psoriasis, is now the first treatment available for PsA and...
MHRA Offers Grace Period for Device Manufacturers Dealing With Withdrawn Notified Bodies

UK – MHRA approves Pfizer/BioNTech’s adapted COVID-19 vaccine (Comirnaty) that targets Omicron XBB.1.5

Approval has today been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech COVID-19 vaccine that targets the Omicron...
Advice for Management of Clinical trials in relation to Coronavirus

UK – Guidance published on the new international regulatory recognition routes for medicines approvals

Following announcement in May of the new scheme to replace the current EC Decision Reliance Procedure (ECDRP) on 1 January 2024, this guidance informs the sector on how...

UK – NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

The NICE committee concluded that the treatment would be an additional ERT for patients with and without an amenable mutation and was a relevant...

USA – FDA publishes additional guidances on delay of enforcing DSCSA electronic tracking requirements

The US Food and Drug Administration (FDA) published two additional guidances with immediate effect that provide more details for trading partners on the one-year...

Europe – PRAC recommends new measures to avoid topiramate exposure in pregnancy

Further restrictions on use; pregnancy prevention programme to be put in place EMA’s safety committee (PRAC) recommends new measures to avoid exposure of children to...
Practical guidance for procedures related to Brexit for medicinal products for human and veterinary use within the framework of the centralised procedure

Europe – COVID-19: Commission authorises adapted COVID-19 vaccine for Member States’ autumn vaccination campaigns

The Commission has authorised the Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech-Pfizer. This vaccine marks another important milestone in the fight against the disease....

Europe – Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5

EMA’s human medicines committee (CHMP) has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant. The vaccine – known as Comirnaty Omicron XBB.1.5...
NHS prepares to fast-track ‘game changing’ cancer drugs that target genetic mutations

UK – NHS world first rollout of cancer jab that cuts treatment time by...

Following the green light from the Medicines and Healthcare products Regulatory Agency (MHRA), the NHS in England will be the first health system in...
Advice for Management of Clinical trials in relation to Coronavirus

UK – Nitrosamines impurities in medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) has assessed the risk of nitrosamine formation or presence during the manufacture of human medicines and...

NOS PROCHAINES FORMATIONS